Review: New Directions in the Optimization of Ocular Drug Delivery

Journal of Ocular Pharmacology

Volumn 6, Issue 2, 1990, Pages 157-164

  Lee, Vincent H l ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; AMPHOTERICIN B; APRACLONIDINE; BETAXOLOL; COLLAGEN; FLUOROURACIL; LEVOBUNOLOL; PILOCARPINE; PROPAMIDINE ISETHIONATE; TIMOLOL; TOBRAMYCIN; TRIFLURIDINE; EYE DROPS;

CONTACT LENS; DRUG DELIVERY SYSTEM; GEL; METHODOLOGY; NONHUMAN; REVIEW; TOPICAL DRUG ADMINISTRATION; ABSORPTION; ANIMAL; BANDAGE; CORNEA; HUMAN;

ABSORPTION; ADMINISTRATION, TOPICAL; ANIMAL; BIOLOGICAL DRESSINGS; COLLAGEN; CORNEA; GELS; HUMAN; OPHTHALMIC SOLUTIONS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0025437233     PISSN: 87563320     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.1990.6.157     Document Type: Article

References (45)

1. Lee, V.H.L. and Robinson, J.R., Topical ocular drug delivery: recent developments and future challenges, J. Ocular Pharmacoo., 2:67–108 (1986).
2. Shaker, G.J., Ueda, S., LoCascio, J.A., and Aquavella, J.V., Effect of a collagen shield on cat corneal epithelial wound healing, Invest. Ophthalmol. Vis. Sci., 30: 1565–1568 (1989).
3. Eswein, M. B., O'Brien, T. P., Osato, M. S., and Jones, D. B., Antimicrobial efficacy of antiseptic-containing collagen corneal shields, Invest. Ophthalmol. Vis. Sci., 31:452 (1990).
4. Desai, D., Thomas, J., Rockey, J.H., and Sahm, D., Use of medicated collagen shields in the treatment of experimental Acanthamoeba keratttis, Invest. Ophthalmol. Vis. Sci., 31:421 (1990).
5. Sawusch, M.R., O'Brien, T.P., Dick, J. D., and Gottsch, J.D., Use of collagen corneal shields in the treatment of bacterial keratttis, Am. J. Ophthalmol., 106:279–281 (1988).
6. Schwartz, S.D., Harrison, S. A. Engstrom, R. E., Jr., Bawden, R.E., Lee, D. A., and Mondino, B.J., Amphoteercin B delivery by collagen shields, Invest. Ophthalmol. Vis. Sci. 31:558 (1990).
7. Gussler, J.R., Ashton, P., Van Meter, W.S., and Smith, T.J., The effect of collagen shields on the topical delivery of trifluorothymidine into cornea and aqueous, Invest. Ophthalmol. Vis Sci. 31:485 (1990).
8. Finkelstein, I., Trope, G.E., Menon, I. A., Spero, L., Rootman, D.S., and Heathcote, G., Further evaluation of collagen shields as adelivery system for 5-fluorouracil (5-FU): Histopathological observations, Invest. Ophtalmol. Vis. Sci. 31:591 (1990).
9. Jacob-LaBarre, J.T. and Kaufman, H.E., Investigation of pilocarpine-loaded polybutylcyanoacrylate nanocapsules in collagen shields as a drug delivery system, Invest. Ophthalmol. Vis. Sci., 31:485 (1990).
10. Ellis, P.P., Matsumura, M., and Rendi, M. A., Pilocarpine concentration in aqueous humor following single drop application; I. Effect of soft contact lenses, Curr. Eye Res., 4:1041–1047 (1985).
11. Pollack, I. P., Harry, A. Q., and Thomas, S. H., The Ocusert pilocarpine system: advatages and disadvantages, Southern Med. J., 69: 1296–1298 (1976).
12. Miller, S.C. and Donovan, M.D., Effect of Poloxamer 407 gel on the miotic activity of pilocarpine nitrate in rabbits, Int. J. Pharm., 12:147–152 (1982).
13. Gurny, R., Ibrahim, H., Aebi, A., Buri, P., Wilson, C.G., Wasshngton, N., Edman, P., and Camber, O., Design and evaluation of controlled release systems for the eye, J. Control. Rel. 6:367–373 (1987).
14. Rozier, A., Mazuel, C, Grove, J., and Plazonnet, B., Gelrite: A novel, ion-activated, in-situ gelling polymer for ophthalmic vehicles. Effect on bioavailability of timolol, Int. J. Pharm., 57:163–168 (1989).
15. Mazuel, C. and Friteyre, M.C., Composition pharmaceutique de type a transition de phase liquide-gel. French Patent Application FR.2588189 Al. Date 87–04–10. Filing Fr. 8514689 date 85–10–03.
16. Moorhouse, R., Colegrove, G.T., Sandford, P.A., Baird, J.K., and Kan, K.S., PS-60: a new gel-forming polysaccharide.In Solution Properties of Polysaccharides, Brandt, D.A., ed., Washington, D.C., 1981, pp. 111–124.
17. Vogel, R. Kulaga, S.F., Laurence, J. K., Gross, R.L., Haik, B. G., Karp, D., Koby, M., and Zimmerman, T. J., The effect of a Gelrite (G) vehicle on the efficacy of low concentrations of timolol (T), Invest. Ophthalmol. Vis. Sci., 31:404 (1990)
18. Doane, M. G., Jense, A. D., and Dohlman, C.H., Penetration routes of topically applied eye medications, Am. J., Ophthalmol., 85: 383–386 (1978).
19. Ahmed, I. and Patton, T. F., Importance of the noncorneal absorption route in topical ophthalmic drug delivery, Invest. Ophthalmol. Vis. Sci. 26:584–587 (1985).
20. Ahmed, I. and Patton, T. F., Disposition of timolol and inulin in the rabbit eye following corneal versus non-corneal absorption, Int. J. Pharm., 38:9–21 (1987).
21. Ahmed, I., Gokhale, R. D., Shah, M. V., and Patton, T. F., Physiocochemical determinants of drug diffusion across the conjunctiva, sclera, and cornea, J. Pharm. Sci., 76:583–586 (1987).
22. Lee, V.H.L., Carson, L.W., and Takemoto, K. A., Macromooecular drug absorption in the albino rabbit eye, Int. J. Pharm., 72: 1272–1279 (1983).
23. Chien, D.-S., Tang-Lui, D.D.-S., and Gluchowski, C, Corneal and Conjuctiva./scleral absorption of α2-adrenergic agents in rabbit eyes, Invest. Ophthalmol. Vis. Sci. 31:403 (1990).
24. Lee, V.H.L., Ashton, P., Bundgaard, H., and Heuer, D. K., Noncorneal route of drug penetration: Role of drug lipophiiicity in determining its contribution to the ocular absorption of beta blockers and timolol prodrugs, Invest. Ophthalmol. Vis. Sci., 31:403 (1990).
25. Grass, G.M., Cobby, J., and Makoid, M.C., Ocular delivery of pilocarpine from erodible matrices, J. Pharm. Sci., 73: 618–621 (1984).
26. Saettone, M.F., Giannaccini, B., Chetoni, P., Gaali, G., and Chiellini, E., Vehicle effects in ophthalmic bioavailability: an evaluation of polymeric inserts containing pilocarpine, J. Pharm. Pharmacol., 36: 229–234 (1983)
27. Attia, M.A., Kassem, M.A., and Safwat, S.M., In vivo performance of [3H]dexamethasone ophthalmic film delivery systems in the rabbit eye, Int. J. Pharm., 47:21–30 (1988).
28. Vasantha, R., Sehgal, P.K., and Rao, K. P., Collagen ophthalmic inserts for pilocarpine drug delivery system, Int. J. Pharm. 47: 95–102 (1988).
29. Urtti, A., Sendo, T., Pipkin, J.D., Rork, G., and Repta, A.J., Application site dependent ocular absorption of timolol, J. Ocular Pharmaaco., 4:335–343 (1988).
30. Wood, R.W., Li, V.H.K., Kreuter, J., and Robinson, J.R., Ocular disposition of poly-hexyl-2-cyano[3- 14C]acrylate nanoparticles in the albino rabbit, Int. J. Pharm., 23:175–183 (1985).
31. Diepold, R., Kreuter, J., Himber, J., Gurny, R., Lee, V.H.L., Robinson, J.R., Saettone, M.F., and Schnaudigel, O.E., Comparison of different models for the testing of pilocarpine eyedrops using conventional eyedrops and a novel depot formulation (nanoparttcles), Graef's Arch. Clin. Exp. Ophthalmol., 227: 188–193 (1989).
32. Kaila, T., Huupponen, R., and Salminen, L., Effects of eyelid closure and nasolacrimal duct occlusion on the systemic absorption of ocular timolol in human subjects, J. Ocular Pharmacol., 2:265–269 (1986).
33. Polansky, J.R. and Alvarado, J.A., Isolation and evaluation of target cells in glaucoma research: hormone receptors and drug responses, Curr. Eye Res., 4: 267–279 (1985).
34. Wandel, T., Charap, A.D., Lewis, R.A., Partamian, L., Cobb, S., Lue, J.C., Novak, G.D., Gaster, R., Smith, J., and Duzman, E., Glaucoma treatment with once-daily levobunolol, Am. J. Ophthalmol., 101: 298–304 (1986).
35. Coleman, A.L., Robin, A.L., Pollack, I.P., and Rudikoff, M.T., A comparison of the cardiovascular effects and intraocular pressure lowering of apraclonidine and timolol, Invest. Ophthalmol. Vis. Sci., 30: 22 (1989).
36. Stein H.H., Giardina, W.J., Ebert, D.M., Cohen, J., Condon, S., Fung, A.K.L., Kleinert, H.D., Luly, J.R., Plattner, J.J., Rosenberg, S.H., and Woods, K., The lowering of intraocular pressure (I0P) in rabbits by topical application of renin inhibitors, The Pharmacologist, 31: 124 (1989).
37. Chang, S.C. and Lee, V.H.L., Nasal and conjunctival contributions to the systemic absorption of topical timolol in the pigmented rabbit: implications in the design of strategies to maximize the ratio of ocular to systemic absorption, J. Ocular Pharmacol. 3:159–169 (1987).
38. Luo, A.M., Heuer, D.K., and Lee, V.H.L., Pharmacokinetic basis for the non-additivity in intraocular pressure lowering of topically applied timolol-epinephrine combinations in the pigmented rabbit, Invest. Ophthalmol. Vis. Sci., 31:232 (1990).
39. Chang, S.C., Chein, D.S., Bundgaard, H., and Lee, V. H. L., Relative effectvveness of prodrug and viscous solution approaches in maximizing the ratio of ocular to systemic absorption of topically applied timolol, Exp. Eve Res., 46:59–69 (1988).
40. Urtti, A., Slaminen, L., and Miinalainen, O., Systemic absorption of ocular pilocarpine is modified by polymer matrices, Int. J. Pharm., 23:147–161 (1985).
41. Sasaki, H. Chien, D.S., and Lee, V.H.L., Differential conjunctival and corneal permeability of β blockers and its influence on the ratio of systemic to ocular drug absorption, Pharm. Res., 5:S98 (1988).
42. Bundgaard, H. (ed.), Design of Prodrugs, Elsevier, Amsterdam (1985).
43. Sasaki, H, Bundgaard, H., and Lee, V.H.L., Design of prodrugs to selectively reduce systemic timolol absorption on the basis of the differential lipophilic characteristics of the cornea and the conjuctiva, Invest. Ophthalmol. Vis. Sci., 30:25 (1989).
44. Ohdo, S., Podder, S., and Lee, V.H.L., Ocular chronopharmacology in the pigmented rabbit: ocular timolol concentrations are dependent on the time of drop instillation, Invest. Ophthalmol. Vis. Sci. 31:232 (1990).
45. Lee, V.H.L., Ohdo, S.F. Podder, S., and Shih, R.L., Maximizing the ratio of ocular to systemic absorption of topically applied timolol in the pigmented rabbit by varying the time of drop instillation, Proceed. Intern. Symp. Control. Rel. Bioact. Mater., 17 (1990) in press.